Introduction to Liver Transplantation

2008-10-31 17:35:08

Introduction to Liver Transplantation
During the next two weeks, HIV and Hepatitis.com will publish a series of
articles that provide information on transplantation issues, with a special
focus on liver transplantation. Provided by the National Institutes of Health
(NIH), the information targets patients and their family caregivers. It is not
intended as medical advice. If you need a transplant, it is important that you
seek the advice and care of qualified transplant physicians.
What is Transplantation?
Transplantation takes place when an organ from one person is surgically removed,
and placed into the body of another person. It is a treatment in situations
where a person's organ has failed because of illness or injury. Replacing the
organ may be the only life-prolonging treatment choice for the patient or the
best among several options.
What Organs Can Be Transplanted?
Solid organs that are transplanted include the heart, lung, liver, kidney,
pancreas, and intestine.
In some cases, two organs are transplanted at once. Examples of this are
heart-lung and kidney-pancreas
Tissues that can be transplanted include:
a.. cornea
b.. bone
c.. cartilage
d.. skin
e.. heart valves
f.. saphenous vein
How Quickly Must an Organ Be Transplanted?
Time is very important in organ transplantation. Most organs need to be
transplanted within a few hours after removal from the donor. Some organs must
be transplanted more quickly than others. This table shows the allowable time
between retrieving the organ from the donor and transplanting the organ into a
recipient. The table compares this allowable time (cold ischemia time) for the
majority of transplanted organs.
Cold Ischemia Time for Solid Organ Transplantation
Organ
Allowable Time from Donor to Recipient (hours)
Heart
4 to 5
Kidney
15 to 18
Liver
12 to 18
Lung
5 to 6
Pancreas
12 to 15
Where Do the Organs Come From?
Most transplanted organs are taken from the bodies of people who have died
(cadaveric or deceased donor transplantation). However, organs such as kidney
and segments of liver can be taken from living organ donors who may be family
members or friends of the person who needs the transplant.
Organs are removed by surgeons in a sterile operating room just like any other
operation. The identification of deceased donors and coordination of organ
retrieval by the surgical teams is the responsibility of 59 Organ Procurement
Organizations (OPOs) across the U.S. Each OPO has a geographic region within
which it serves hospitals where potential donors have been identified.
What Factors Determine Which Patient Will Receive a Particular Donor Organ?
Everybody who is a candidate for a cadaveric organ transplant in the U.S. is
placed on a national waiting list. There are specific government regulations
that guide the allocation process. Under a government contract, the nation's
Organ Procurement and Transplantation Network formulates allocation policy based
on input from transplant professionals, patients, donor groups, and the public.
Ultimately, these policies determine, for any given donor, which waiting patient
has the highest priority. The rules are fairly complicated and vary by organ
type.
Two major issues are considered: allocation rules and geographic distribution.
Generally, when an organ becomes available, it is allocated to the person on the
local OPO's waitlist who has the most urgent need (liver and heart) combined
with other medical considerations and ranking of patients according to who has
been waiting the longest time.
Organs are usually offered first to patients waiting at transplant centers
within the OPO's service area, then to patients in that OPO's region (there are
11 defined geographic regions in the U.S.), and then to patients anywhere else
in the U.S.
Next article in this series: Liver Transplant (to be posted Wednesday, May 14,
2003)
05/12/03
Source
National Institutes of Health (NIH)
http://www.hivandhepatitis.com/hep_c/news/051203a.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

How to Reduce the Risk of Infection with Hepatitis C?

2008-10-31 09:43:47

How to Reduce the Risk of Infection with Hepatitis C?
In the United States, hepatitis C virus (HCV) infection is now the most common
chronic blood borne infection. HCV currently infects more than 3 million people
in the United States and 175 million people globally. Over 80 percent of
HCV-infected individuals go on to develop chronic disease.
Most patients remain asymptomatic despite the insidious progression of the
disease.
The consequences of HCV-induced chronic liver disease account for 8,000 to
10,000 deaths annually in the United States and is currently the leading
indication for liver transplantation. The cost of the HCV epidemic to the United
States was estimated in 1991 at $600 million in terms of medical expenses
(excluding costs related to liver transplantation) and work lost.
Because the early stages of the disease are usually asymptomatic, many persons
with chronic HCV infection are unaware that they are infected and may
unknowingly expose others to the virus. This article brings primary care
physicians up to date on current recommendations for reducing the risk of
infection with hepatitis C.
The author begins by reviewing those groups who are more at risk for contracting
the disease: transfusion and transplant recipients, injection and other illegal
drug users, patients undergoing dialysis, health care workers, persons with
tattoos or body piercing, persons with multiple sex partners, long term sex
partners of HCV positive persons, household contacts of HCV positive persons,
and children of HCV positive mothers.
Recommendations are offered for determining who should be tested for HCV
infection. The article concludes with a section of suggestions for the
prevention of HCV transmission, in the categories of blood, blood products and
transplanted organs and tissues; illegal drug use; high risk sexual practices;
occupational exposure to blood; home infusion therapy; long term hemodialysis;
and tattooing and body piercing.
These recommendations are highlights of the CDC recommendations aimed at
reducing the transmission of HCV and lowering the risk of serious liver disease
in persons with chronic HCV infection.
Major Descriptors (MJ): Digestive System Diseases. Hepatitis C. Transmission.
Prevention. Guidelines. Risk Factors.
Minor Descriptors (MN): Human Viral Hepatitis. Organ Donation. Transplantation.
Blood Donation. Bloodborne Diseases. Occupational Safety. Substance Abuse.
Sexually Transmitted Diseases. Hemodialysis. Body Piercing. Liver Diseases.
05/12/03
Source
Primary Care Update: Brief Summaries for Clinical Practice 40(2): 245-248.
February 2000.
http://www.hivandhepatitis.com/hep_c/news/051203b.html
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Re: [HepCingles2] Hi there

2008-10-31 09:15:37

Pam,
I am so sorry to hear you are not feeling well.
I actually felt ok today. I even got a little yard work done. I am sure I will
pay for it tomorrow.
I hope you feel better soon.
Hugs,
Vicki

Hi there

2008-10-31 03:39:26

presently going to tx and doing ok so far ,,any one for a
talk ....email me or IM me .....

Re: [HepCingles2] looking to meet swf with hep c

2008-10-30 14:43:46

How's it goin, groovey I hope..Sorry can't help w/the search but can be here if
you need to vent .I am sure you find that special someone and really really hope
you do let me know.Take care and above all be happie.....
Look to the past, Live in the present & Forge the future
author unknown,

Giving up anonymity to fight Hep C

2008-10-30 14:21:27

The Courage to be A Voice
Ron Metcalfe was told to keep his diagnosis of Hepatitis C secret. As many
patients know, the disease carries with it the stigma of being a "junkie
disease," thus putting the "blame" for contracting the disease on the patient.
Metcalfe decided to become a voice for HCV patients, by starting a blog,
revealing his identity and diagnosis. According to the BBC, "His was the first
UK blog by someone living with and having treatment for hepatitis C." Read Ron
Metcalfe's story. Then read his wonderful blog.
http://hepatitis.about.com/gi/dynamic/offsite.htm?zi=1/XJ&sdn=hepatitis&zu=http%\
3A%2F%2Fwww.ronmetcalfe.com%2Fblog%2F
http://hepatitis.about.com/b/a/256576.htm
Giving up anonymity to fight Hep C
By Jane Elliott
BBC News health reporter
When Ron Metcalfe was first diagnosed with hepatitis C he was
advised to keep it a "secret" because of the stigma linking it to injecting drug
use.
But Ron was determined to do the exact opposite.
So he set up a website to provide support for others in the same
position as himself, as well as to chronicle his own fight with the potentially
fatal condition.
His was the first UK blog by someone living with and having
treatment for hepatitis C.
Secret
"It was a total shock when I was first diagnosed. I had never heard
of hepatitis C. I barely even knew where my liver was," he said.
"After being advised not to disclose my diagnosis, I kept it
'secret' for several months, but I felt uncomfortable about being dishonest when
people asked 'how are you?'.
"When I began to tentatively tell some people I encountered no
stigma, so then became straightforward about it with people - which felt much
easier and more in keeping with my nature."
As he started his arduous treatment, Ron, a family man and a
professional counsellor in his 50s, from London, decided to strike a blow for
the "silent majority" with hepatitis C who were too frightened to speak about
their condition.
"I decided to write a blog. I thought a lot about this issue of
'keeping it quiet' and decided this feeds into the stigma and continues it.
"It will only be when people like myself straightforwardly identify
themselves as having this virus that the stigma will be challenged - it is not
just injecting drug user who get this virus.
"So I decided it was important to use my full name and own up that I
have the virus although I am not an injecting drug user. I have never
experienced any discrimination or judgement from the people I tell."
A recent report by the Hepatitis C Trust said Britain was "failing"
on hepatitis C and unless urgent action was taken on tackling it, thousands of
patients could die prematurely.
One of the major problems was that many people with the disease were
unaware that they had it and so they did not take action, it said.
Ron is unclear when or how he contracted the virus, but suspects it
could have been either from blood products used in an operation he had in
Canada, an unhygienic dentist he visited, or mass inoculations he had.
Fight
But he says that the reasons for the virus are unimportant and that
the important factor is beating it.
"If there is a stigma about having hep C, it is that it's the virus
of injecting drug users - who by implication, have only themselves to blame for
catching it.
"There are a great number of people with hep C for whom injectable
drugs are not part of their lifestyle - career professionals like myself,
haemophiliacs, health care professionals.
"None of us, including injecting drug users, deserves to have this
virus and none of us 'have only ourselves to blame'."
Prior to diagnosis, Ron had been feeling unwell for some time. He
suffered pains, fatigue and digestive problems for a number of years and doctors
feared he might have irritable bowel syndrome.
"I got to the point of being exhausted and to the point of being
emotionally weepy and tired. My GP thought I might be depressed and prescribed
Prozac which I took. I had various skin rashes and I have still got liver spots.
"I had a number of things like that and it was finally when I was
feeling like I had flu and could not get out of bed that I want back to the GP
and said that I was ill."
As Ron explained, the symptoms are very vague and easily missed, for
which he blames no one.
He was told he would have to undertake the 48-week Pegasys, or
pegylated interferon, treatment.
Before undertaking the course and during it, Ron kept himself
healthy, gave up drinking, improved his diet and had complementary therapies to
rid his body of toxins. He also did regular yoga.
Virus
Tests at the 12-week stage showed that Ron's hepatitis C was
"undetectable" and he hopes that the drugs course, which has a 50% success rate
will prove a "cure" in his case.
"They do not say though that you have been cured, if it works, they
just say the virus is undetectable, because in the future they might have even
more rigorous tests which might then be able to detect it."
But he is hopeful that all his careful work protecting his body will
stand him in good stead.
"I think I have a good chance. My commitment to my liver goes above
and beyond the medical advice."
About 200 people a day visit Ron's blog, which records his struggle
with the treatment.
Trawls of his site reveal that not only is it avidly read by others
with the disease, but it is also used by health professionals and specialists as
it provides a grassroots account of living with hepatitis C.
Ron says blogs like his help provide a support group for others with
the condition.
It is proving so popular that he has been approached by a drug
company looking at funding a pilot scheme which would allow the blog to be used
within the NHS for this and other conditions.
This could give bloggers protected confidentiality and might even
include a professional in the role as "webmaster" to answer questions and
provide support and encouragement.
http://hepatitis.about.com/gi/dynamic/offsite.htm?zi=1/XJ&sdn=hepatitis&zu=http%\
3A%2F%2Fnews.bbc.co.uk%2F2%2Fhi%2Fhealth%2F4229962.stm

looking to meet swf with hep c

2008-10-30 05:59:48

I am a swm recently diagnosed with hep c. I would like to meet a swf
also with hep c for companionship. I currently live in southwestern
Ontario. I am easy to get along with and have a great sense of humour
at 40 years young!!

Class-Action Lawsuit by Inmates Demands Treatment for Hepatitis C

2008-10-30 04:01:46

http://www.hivandhepatitis.com/hep_c/news/050703a.html
Class-Action Lawsuit by Inmates Demands Treatment for Hepatitis C
Oregon inmates allege in a pending class-action lawsuit that treatment for
hepatitis C is so woefully inadequate in the state's 12-prison, 11,800-inmate
system that it violates the constitutional ban on cruel and unusual punishment.
Prisoners say health care managers systematically deny treatment to hold down
costs.
The federal lawsuit seeks $17.5 million for inmate medical expenses, including
drug therapy, chemotherapy and potential liver transplants. "It's just
unconscionable what's going on," said Phyllis Beck, director of the Hepatitis C
Awareness Project in Eugene, Ore. "They're letting prisoners die of hepatitis
C." Beck said, "The main reason a lot of these prisoners aren't getting
treatment is because of the cost."
Portland lawyer Michelle Burrows filed the suit on behalf of 11 current and
former inmates. District Court Judge Anna Brown recently granted Burrows' motion
to expand the suit into a class action. All Oregon inmates with hepatitis C now
are considered plaintiffs. Corrections Department spokesperson Perrin Damon
said, "Treatment protocol is both medically appropriate and conforms with the
state's legal obligation to provide medical care to state prison inmates. We
look forward to responding to the plaintiffs' claims in court."
Corrections officials estimate that about 30 percent of all Oregon inmates -
roughly 3,500 - are infected with hepatitis C. Corrections Department Medical
Director Dr. Steve Shelton, who oversees the prison system's management of
hepatitis C, declined to provide complete data on the number of prisoners given
medication for the infection.
In 2001, the only data made available by the department, a dozen inmates
received the drug therapy. At a low-end cost of $18,000 per inmate, providing
treatment for 10 percent of the infected inmates in Oregon would cost taxpayers
at least $6.3 million. At a high-end cost of $30,000 per inmate, the total bill
would rise to $10.5 million.
05/07/03
Sources
A Gustafson. Class-Action Lawsuit by Inmates Demands Treatment for Hepatitis C.
Associated Press. May 5, 2003.
CDC HIV/STD/TB Prevention News Update. May 5, 2003.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

1948 GIs Key to HepC

2008-10-29 13:32:51

Hi Corey........ I hope you are on this list too!! LOL I know you asked about
the history of Hep C on another list but I don't do info posts on that list so I
am putting it here :-) Anyone NOT interested please just delete :-) I did
a search on MY computer......... not on google........ and came up with these
three *old* emails...........I am sure they will lead to others on Google but I
haven't had a chance to go there yet. I am sure this will point you in the
right direction.......... Take care of yourself!

More Blood Donors Post-9/11, but Blood Supply Safe

2008-10-29 09:14:20

More Blood Donors Post-9/11, but Blood Supply Safe
20 minutes ago
By Alison McCook
NEW YORK (Reuters Health) - About two-and-a-half times as many blood donations
were collected in the U.S. the week after the September 11 attacks than during
the weeks preceding the disaster, researchers said Tuesday.
Yet despite this increased burden on screening for blood-borne viruses, the
influx of new donors probably had no significant impact on the safety of the
blood supply, they report in the Journal of the American Medical Association
(news - web sites).
A particularly large response was seen from first-time donors, who offered more
than five times as many donations during the week after September 11 than in the
weeks preceding the attacks. In contrast, the number of donations from repeat
donors increased by 50 percent during that first week.
First-time donors tend to have higher rates of HIV (news - web sites) and
hepatitis, infections that can be transmitted to transfusion recipients. All
donated blood is screened for the presence of these viruses, but in very few
instances -- less than six per one billion units -- these screening tests may
mistakenly indicate that donated blood is virus-free.
But despite the fact that more people gave blood for the first time after
September 11, this flood of first-time donors did not last long. And given that
the risk of missing viruses in blood donations is very small, people who
received transfusions collected immediately after September 11 likely have no
increased risk of falling ill as a result, the researchers report.
"Our data suggested that the increase in viral risk that may have occurred
because of this influx of first-time donors would have been small and
short-lived, and probably did not significantly impact blood safety," study
author Dr. Simone A. Glynn, of the research corporation Westat in Rockville,
Maryland, told Reuters Health.
Her team also found that few of the first-time donors became repeat donors, as
less than one-third had returned to give blood by the week of September 11 the
following year -- a return rate typical of first-time donors.
These findings indicate that while Americans respond well during periods of
crisis, more education about the ongoing need for blood donations is needed,
according to Glynn.
"Many first-time donors may not realize that blood is needed everyday to save
the lives of accident victims or patients with cancer," she said.
"There have been increasingly significant blood shortages with resulting
postponements of elective surgeries in some areas of the country. It appears
that there is a general need for education about the importance of regular blood
donations," she added.
Glynn and her colleagues estimated the nationwide patterns of blood donations
before and after the September 11 attacks based on data from five large blood
donation centers, which collected eight percent of the country's blood supply.
SOURCE: Journal of the American Medical Association 2003;289:2246-2253.

HCV March on DC May 23

2008-10-29 05:48:10

Hepatitis C's Movement for Awareness
National March Agenda May 22 - 24 2003
Scheduled Events:
We're all staying at the
Holiday Inn Downtown D.C.
1155 14th Street, N.W. Washington D.C. 20005
Call (202)737-1200 extension 1137 (ask for Mr. Pernell or
Beverly Rowe). The rooms are under HCV NATIONAL MARCH.
Please ask for THESE rooms, as they are blocked off for us at
special rate of $89.
The Holiday Inn, located in the heart of the Central Business
District and the East End at the intersection of 14th Street and
Massachusetts Avenue, is within walking distance to the White
House, Convention Center, Smithsonian, MCI Center, Embassy
Row, Jefferson, Lincoln and Vietnam Memorials, as well as
many popular downtown restaurants and shops.
View Hotel info here
http://unitedstates.biz/dc/washington/hotels/holiday-inn-downtow
n-tn170092.html
This website will print out driving directions
http://www.mapquest.com/directions/main.adp
Reagan National Airport is three miles away.
Here is a list with more information on travel and lodging in DC
http://hcvets.com/forum_public/hma/info/hma/travel/travel.htm
Please try to stay at Holiday Inn Downtown. Several Events will
take place in and around the hotel. The schedule is as follows:
Thursday Evening 5/22
7:00 pm- Kick Off Rally (Holiday Inn Downtown) with open
registration and a silent auction to benefit awareness. The items
include a private 3500-sq.ft. Five-bedroom holiday villa on St.
Lucia Island, West Indies. One week stay for five people, to be
used by September 30, 2003. The total cost to you is $500 for
servants and maintenance to be paid to the owner, if you win the
bid. Over $2500 retail value. View Villa here
http://www.brigandhill.com/

Friday Morning 5/23
10:00 am -Rally on the National Mall, located at 3rd Street across
from the Capitol
Friday Afternoon 5/23
1:00 - 4:00 p.m.- Freedom Plaza 14th and Pennsylvania Ave
7:00 pm Diner and raffle at the HollidayInn Downtown
Friday Evening 5/23
7:00-9:00 p.m-. Dinner at the Holiday Inn Downtown. Reserve a
Welcome Packets now, for $20.00, which includes one dinner
ticket for Friday night after the march and one T-shirt. A savings
of $11.00 {plus there is useful information about the area} Call
540 248 4994 or view this website to reserve online..
http://hcvets.com/campaigns/2003/agenda.asp The packets can
also be purchase at the rally Thursday Night, while supplies last.
Saturday Day 5/24
During the day- optional most members will participate in
scheduled Memorial Day events, some will tour the city.
Tricia (HMA National Coordinator) will meet, one on one, with any
that would like. Please schedule a time with Wendy Wright at
Wrightinfotek@... 540 248 4994 or during the events,
540 448 0104.

Saturday Evening 5/24
7:00 pm- Candlelight vigil held at Thomas Circle National Park
Massachusetts & Vermont Ave.
(Across from the Holiday Inn Downtown)
Add names to the list at this website
http://hcvets.com/forum_public/hma/disc.htm
Participants will light candles and read names in remembrance
of all those that passed from this devastating disease. Many will
bring pictures also.
The International Quilts will be on display all three days. Bring
your square for future quilts.
Keep updated on the latest information about the National March
at http://hcvets.com/forum_public/hma/disc.htm
This years March for Awareness is sponsored by Hepatitis C's
Movement for Awareness & Supported by the Latino Organization
for Liver Awareness, with Contributions from Vietnam Veterans
of America, Fisher Pharmacies, Roche Biological Inc.

Welcome new members!

2008-10-29 00:47:14

Hey everybody! Sorry I have been MIA...... I have been really busy lately. I
wanted to welcome all the new members......... especially Ken, Mike, and Teri
who have been kind enough to introduce themselves and share a little with us
:-) I hope that everyone is doing well today and even if I don't get to post
and *chat* the way I would like I will always try to keep those info posts
coming :-) I always like learning all I can about this (and other) diseases!
Remember to look around and make yourselves at home. We a good links page and
we have a great photo section and would love for EVERYONE to add their photo
when they can. It is always so great putting faces to names. Well I am off
and running...... take care of yourselves!
Peace and Love,
·´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"There are many intelligent species in the universe. They are all owned
by cats." - Anonymous
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/25/2003

Shake it??

2008-10-28 15:54:52

Cleaning out my mail box and ran across this........ I still like it :-)
http://www.lebonze.co.uk/stuff/move.htm
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Re: [HepCingles2] New to Group....Hey Hutch

2008-10-28 13:57:12

Itching...... Mine started on my forearms right at the elbows.........then
gradually it has spread all over my body........seemingly the worst effected is
my feet which are scaling and peeling..........deep to the bone itching....now I
got it every where (itching)....I went to the dermatologist who made up some
cream w/menthol and it seems to work okay......... Schering-Plough...... go to
www.schering-plough.com look for "commitment to care" print of the forms out and
get your Dr. to fill out his portion and you fill out the top portion and have
the Dr.'s office mail to schering-plough. I am still waiting to find out if I
will/ not get approved. They send you a 3 month supply then you re-order more
with aform they give you for more....My Dr. is wanting me on 32-48 week
treatment.... Also ask PeachStatePam I think she knows of some other programs
if that does not work.......look at her previous posts to me in the group... I
know what you are going through........Keri Lotion -or- Lubriderm /
Hypoallerginic should help you get through. Also I have found that a tepid
shower with Lever 2000 aloe vera soap and pat dry helps pretty good for a little
while... check out this magazine if you don't have it
already:www.hepatitismag.com Really informative and useful! Hutchinson....
William Keith Denison <keithrockerdude@...
Where's Starsky? (just kidding). I'm Keith in San Jose, Ca. I was
wondering about your itching.
Just the other day the tops of my forearms were itching at night. for a
few hours. I don't know if I came in contact with something or what, but
I don't think that I did. Anyway, I hope your doing well. So
Schering-Plough Will cover meds for 3 months? What if you need them for
6, or a year? I need help getting meds too. No ins.
Take care,
Keith

Stay Up To Date w/the latest Hepatitis C advancements

2008-10-28 01:58:06

Hepatitis C in the News
Stay up to date with the latest hepatitis C medical advancements and research
trends.
Start by browsing our special News Review section, with includes
easy-to-understand re-writes of some of the most complicated treatment issues
and medical discoveries.

Gas War~An Idea that COULD work

2008-10-27 21:13:10

This was originally sent by a retired Coca Cola executive. It
came from one of his engineer buddies who retired from Halliburton. It'
s worth your consideration.
Join the resistance!!!! I hear we are going to hit close to $4.00 a
gallon by next summer and it might go higher!! Want gasoline prices to
come down? We need to take some intelligent, united action. Phillip
Hollsworth offered this good idea.
This makes MUCH MORE SENSE than the "don't buy gas on a certain day"
campaign that was going around last April or May! The oil companies just
laughed at that because they knew we wouldn't continue to "hurt"
ourselves by refusing to buy gas. It was more of an inconvenience to us
than it was a problem for them. BUT, whoever thought of this idea, has
come up with a plan that can really work. Please read on and join with
us! By now you're
probably thinking gasoline priced at about $1.50 is super cheap. Me
too! It is currently $2.79 for regular unleaded in my town. Now that the
oil companies and the OPEC nations have conditioned us to think that the
cost of a gallon of gas is CHEAP at $1.50 - $1.75, we need to take
aggressive action to teach them that BUYERS control the marketplace.....
not sellers. With the price of gasoline going up more each day, we
consumers need to take action. The only way we are going to see the
price of gas come down is if we hit someone in the pocketbook by not
purchasing their gas! And, we can do that WITHOUT hurting ourselves.
How? Since we all rely on our cars, we can't just stop buying gas. But
we CAN have an impact on gas prices if we all act together to force a
price war.
Here's the idea:
For the rest of this year, DON' T purchase ANY gasoline from the two
biggest companies (which now are one), EXXON and MOBIL. If! they are not
selling any gas, they will be inclined to reduce their prices. If they
reduce their prices, the other companies will have to follow suit. But
to have an impact, we need to reach literally millions of Exxon and
Mobil gas buyers. It's really simple to do! Now, don't wimp out at this
point.... keep reading and I'll explain how simple it is to reach
millions of people. I am sending this note to 30 people. If each of us
sends it to at least ten more (30 x 10 =3D 300) ... and those 300 send
it to at least ten more (300 x 10 =3D 3,000)...and so on, by the time
the message reaches the sixth group of people, we will have reached over
THREE MILLION consumers. If those three million get excited and pass
this on to ten friends each, then 30 million people will have been
contacted! If it goes one level further, you guessed it..... THREE
HUNDRED MILLION PEOPLE!!!Again, all you have to do is send this to 10
people. That's all. (If you don't understand how we can reach 300
million and all you have to do is send this to 10 people.... Well, let's
face it, you just aren't a mathematician. But I am, so trust me on this
one.) How long would all that take? If each of us sends this e-mail out
to ten more people within one day of receipt, all 300 MILLION people
could conceivably be contacted within the next 8 days!!!! I'll bet you
didn't think you and I had that much potential,
did you?Acting together we can make a difference. If this makes sense to
you, please pass this message on. I suggest that we not buy from
EXXON/MOBIL UNTIL THEY LOWER THEIR PRICES TO THE $1.30 RANGE AND KEEP
THEM DOWN. THIS CAN REALLY WORK.
~Bayla~
SVRnWaiting
"C" It! Treat It! Beat It!!
http://hometown.aol.com/nydragonslayer/

Re: [HepCingles2] New to Group.Mike NC

2008-10-27 19:56:32

Hi Mike,
I'm Keith in San Jose, Ca. How did your commitment to care program go? I
need the same type of help possibily. No ins. Do you feel better yet?
Have more energy? How are your sides? Over all, how pleased are you that
you did tx? Or is it too soon to tell? Hope you are well.
Sincerely,
Keith

Re: [HepCingles2] New to Group....Hey Huch

2008-10-27 13:01:37

Hey Huchinson,
Where's Starsky? (just kidding). I'm Keith in San Jose, Ca. I was
wondering about your itching.
Just the other day the tops of my forearms were itching at night. for a
few hours. I don't know if I came in contact with something or what, but
I don't think that I did. Anyway, I hope your doing well. So
Schering-Plough Will cover meds for 3 months? What if you need them for
6, or a year? I need help getting meds too. No ins.
Take care,
Keith

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.

2008-10-27 10:59:59

Steatosis and progression of fibrosis in untreated patients with chronic
hepatitis C infection.
Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, Liang TJ,
Hoofnagle JH, Ghany MG.
Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD.
Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is
reported to be a risk factor for progression of fibrosis. The aims of this study
were to evaluate the interactions between hepatic steatosis and fibrosis in a
well-defined cohort of patients with CHC. The computerized pathology database at
the National Institutes of Health Clinical Center was searched for patients with
CHC who had undergone liver biopsy between 1980 and 2003. Biopsies were scored
for necroinflammation using a modified histology activity index, fibrosis using
the Ishak system, and steatosis as either none (<5% of cells), mild (5%-25%), or
moderate-to-severe (
The mean age was 44 +/- 9.8 years; 60% were male, 80% Caucasian, and 65% were
infected with genotype 1. Steatosis was mild in 31% and moderate to severe in 9%
of patients. In univariate analysis, steatosis was associated with increased
age, body weight, body mass index (BMI), alanine aminotransferase (ALT) levels,
histological necroinflammatory activity, and fibrosis. However, in multivariate
analysis, steatosis was associated only with increased age, BMI, and ALT levels
and not with fibrosis. One hundred thirty-six patients had 2 liver biopsies
separated by 0.5 to 17 years. Worsening of fibrosis occurred in 40% of patients
and correlated independently with increasing age, periportal necroinflammation,
and ALT elevations but not with steatosis. In conclusion, in this cohort of
patients with CHC, steatosis was associated with older age, higher BMI, and
higher serum ALT levels but not with the presence of or subsequent progression
of fibrosis. (HEPATOLOGY 2006;43:780-787.).
PMID: 16557550 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1\
6557550&dopt=Abstract

DiscoveryHealthChannel.com Liver Transplantation

2008-10-26 19:16:15

http://health.discovery.com/diseasesandcond/encyclopedia/882.html
Liver Transplantation
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Sarna for itching

2008-10-26 13:18:14

I was cleaning out my inbox and was reminded about Sarna........ a great lotion
for itching that many swear by.......... Here is a link :-) Hope this helps
someone!
http://www.dermadoctor.com/pages/branddetail22.asp?x=1&WID=%7BBACB863B%2D35D1%2D\
11D6%2D9175%2D0002B330452B%7D
Peace and Love,
·´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"There are many intelligent species in the universe. They are all owned by
cats." - Anonymous
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Re: [HepCingles2] Another newbie

2008-10-26 12:20:58

Welcome to the group and sorry to hear that another person has fallen victim to
the silent dragon.....I too am still trying to get used to although I have had
my diagnosis since 9/02. I am trying to get my treatments started but the $$$
to do this are wayyyyyy to high....luckily the mfg. of peg-itron and rebetol
have a program for dealing with the financial aspect of this disease. Have a 13
million + enzyme count with genotype 1A. I am in Hutchinson Kansas........keep
in touch if ya want............. Hutchinson Hepper
Teri Shoal <teri_shoal@...
Hi all,
I'm Teri, a 48 year old single female who lives north of Seattle, WA.
My Hep C diagnosis came in January and I'm still working at getting used to
the idea that I have it. Life's full of bumps, hills and mountains isn't it?
This is one of those very large hills, but not too high to climb I don't
think.
I'm fairly active and have a sea kayak and a mountain bike with which to
explore the great northwest. I'd like to connect with some Hep C singles in
the area and I look forward to talking with all you listers too! Thanks for
making lists like this available to us all.
All my best,
Teri

Another newbie

2008-10-26 05:38:23

Hi all,
I'm Teri, a 48 year old single female who lives north of Seattle, WA.
My Hep C diagnosis came in January and I'm still working at getting used to
the idea that I have it. Life's full of bumps, hills and mountains isn't it?
This is one of those very large hills, but not too high to climb I don't
think.
I'm fairly active and have a sea kayak and a mountain bike with which to
explore the great northwest. I'd like to connect with some Hep C singles in
the area and I look forward to talking with all you listers too! Thanks for
making lists like this available to us all.
All my best,
Teri

Re: [HepCingles2] New to Group....

2008-10-26 04:16:33

I just finished the commitment to care program.Its a wonderful program if
your poor.I had no problem getting help.lol.As far as the itching goes ,Lot
and lots of water helped me...Good luck and God bless ...Mike NC

Re: [HepCingles2] Ken - new to group

2008-10-25 20:04:52

Welcome to the group......
Ken <CherokeePride37@...
Ken. I'm a 37 year old
male residing in Florida but hope to move to vermont in the near
future.
My hobbies include camping, travel, dining out, movies, music,
cooking,spending time with youngsters, pets,basically just enjoying
the simple things in life.
I look forward to getting to know you all.
Thanks.
Ken

Ken - new to group

2008-10-25 06:11:56

I just want to introduce myself. My name is Ken. I'm a 37 year old
male residing in Florida but hope to move to vermont in the near
future.
My hobbies include camping, travel, dining out, movies, music,
cooking,spending time with youngsters, pets,basically just enjoying
the simple things in life.
I look forward to getting to know you all.
Thanks.
Ken

Saturday Night CHAT!

2008-10-25 00:22:30

Have Hepatitis C? Want to talk? Please meet us at the HepCat Hideout Chat at
http://forums.delphiforums.com/HepCingles
on Saturday nights at 5pm PST which is 8pm EST until 2AM EST or later!
**THIS IS A NEW EARLIER TIME**
You do NOT have to be single to attend!! EVERYONE with Hep C or interested in
Hep C or caring for someone with Hep C is encouraged to attend. If someone is
not there PLEASE hang out for awhile and they will show up shortly :-) Hope
everyone has a wonderful weekend and I am sorry I didn't get this out in a more
timely manner........the 8PM is a new time and people should be *in and out*
until 2AM EST Is it be there or be square?...... or be there or be talked
about?? LOL Take care all!!
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

LifeSharers Members Newsletter

2008-10-24 23:04:31

LifeSharers Members Newsletter
May, 2003
MEMBERSHIP UPDATE
As of April 30th, LifeSharers has 736 members. This represents a 12% increase
over last month's total of 658. We have members in 43 states and the District
of Columbia.
As of April 30th, 148 of our members have qualified for preferred access to the
organs and tissue of fellow members. Members are eligible for preferred access
180 days after joining LifeSharers. If you have qualified for preferred access,
please let us know if you
are also on the UNOS waiting list for an organ.
We will make available to UNOS and Organ Procurement Organizations a list of our
qualified members who are on the UNOS waiting list.
Please tell your friends and family about LifeSharers. Every new member
decreases the chance you'll die waiting for an organ.
PRESS COVERAGE OF LIFESHARERS
Capital 9 News Albany - April 26, 2003
http://www.capitalnews9.com/content/headlines/?ArID=24141&SecID=33
PNNOnline - April 25, 2003
http://www.pnnonline.org/article.php?sid=4391
The Times-Picayune - April 22, 2003
http://www.nola.com/news/t-p/index.ssf?/base/news-0/1050990941125910.xml
WINK Ft. Myers TV Channel 11 - April 17, 2003
http://www.winktv.com/local/show_news.php?show_n_id=3791&clean=1
2002 LIFESHARERS FINANCIAL REPORT
In its first calendar year of operation, LifeSharers had revenues of $5,703.
All revenue came from gifts, with the exception of a small amount of interest
income. Gifts from the founder of LifeSharers were $5,486. Gifts from others
were $213. Interest income was $4.
In its first calendar year of operation, LifeSharers spent $4,277.
Expenditures were $3,086 for computer hardware and software, $493 for web site
operations, $369 for marketing, $250 for start-up expenses, $71 for office
supplies and postage, and $8 for bank fees.
At December 31, 2002, LifeSharers had monetary assets of $1,426.
Estimated operating expenses for the year 2003 are $2,900.
PLEASE HELP SUPPORT LIFESHARERS
LifeSharers is staffed by volunteers, and we get all our financial support from
our members. Please send us a financial contribution. We'll put it to good use
recruiting new members and maintaining our web site and member database. To see
how easy it is to contribute to LifeSharers go here:
http://www.lifesharers.com/contribute.htm
LifeSharers is a qualified 501(c)(3) non-profit organization. Contributions to
LifeSharers are tax-deductible to the fullest extent of the law.
OTHER NEWS
What if you had the chance to save a life?
http://www.suntimes.com/output/brown/cst-nws-brown21.html
Texas mulls policy for organ donation by presumed consent
http://www.ama-assn.org/sci-pubs/amnews/pick_03/prsd0428.htm
Organ and tissue donors honored on National Donor Memorial web site
http://www.unos.org/news/newsDetail.asp?id=264
FDA approves trials on eliminating need for immunosuppressant drugs
http://louisville.bizjournals.com/louisville/stories/2003/04/07/story2.html
Arizona to activate organ donor registry
http://www.azdailysun.com/non_sec/nav_includes/story.cfm?storyID=63320
Tricking the immune system to accept transplanted organs
http://www.courier-journal.com/localnews/2003/04/05/ke040503s392450.htm
Muscle cell injections may help failing hearts
http://www.heartcenteronline.com/myheartdr/home/research-detail.cfm?reutersid=34\
98
Thanks again for your support.
Dave Undis
Executive Director
daveundis@...
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Body Piercing: Do So at Your Own Risk

2008-10-24 16:43:15

Body Piercing: Do So at Your Own Risk
Fri Apr 11,11:46 PM ET
By Amanda Gardner
HealthScoutNews Reporter
FRIDAY, April 11 (HealthScoutNews) -- In the fall of 2000, seven Oregon youths
were infected with a dangerous bacterium after having their upper ear cartilage
pierced at a local mall.
Five were hospitalized, and three others had to undergo reconstructive surgery
to fix deformities in their ears.
The surprising thing was not that the youths, aged 10 to 19, became infected,
but that the public even heard about the cases.
"A lot of people might encounter complications [from body piercing], but they're
never counted," says Myrna Armstrong, a professor in the school of nursing at
Texas Tech University in Lubbock.
Armstrong's research has revealed a 45 percent infection rate from navel
piercing. And she's discovering even more problems with "high rim" -- or ear
cartilage -- piercing.
Although it's notoriously difficult to track the complications resulting from
this form of body art, interviews with experts indicate that problems are common
and sometimes even life-threatening.
One person had a near-fatal hemorrhage requiring multiple transfusions as a
result of a tongue piercing, says Dr. Lester B. Mayers, director of sports
medicine at Pace University in Pleasantville, N.Y. Another person with a freshly
pierced tongue contracted an infection that closed the airways and forced a
lengthy hospital stay.
The risk of contracting hepatitis B or C is also very real, says Dr. Sandra
Kemmerly, an infectious disease specialist at the Ochsner Clinic Foundation in
New Orleans. Presumably, HIV (news - web sites) transmission is a risk as well,
she adds.
Despite the hazards, body piercing is increasingly popular.
An article in the February 2001 issue of the Journal of School Nursing found a
283 percent rise in the number of body art studios in Texas between 1994 and
1998.
And a survey by Mayers of 454 students found that 60 percent of female students
had one or more piercings in places other than their earlobes, and 42 percent of
males had piercings in their earlobes and elsewhere.
"We're talking about a very large number of people," Mayers says. "Even if it's
a small percentage of complications that can be a large number because of the
huge number of people who have the procedures."
Some of the most serious complications have resulted from tongue piercing.
"That's where we see the biggest problems," Kemmerly says. "I've seen cases that
required antibiotics for long periods of time. The tongue was all swollen. The
person couldn't eat. It was just gross."
The reason is the preponderance of bacteria that inhabit the mouth.
"We have provided a portal of entry for bacteria into the body," says Dr.
Matthew Messina, a spokesman for the American Dental Association. "We've
basically said, 'Come on in.' We've intentionally opened a wound and are not
permitting it to heal, so find me a reason why this is good."
The American Dental Association has issued a statement opposing oral piercing.
One reason: Infections can close off the airway, potentially resulting in death.
And don't forget damage to teeth, including chipping, fractures, gum abrasion
and tartar and plaque build-up, the ADA says.
"In life we make decisions and balance the risks and benefits and this is a
procedure with some serious and potentially life-threatening risks which I have
yet to see a benefit to," Messina says.
Traveling south, the belly button is another area prone to infection. "It's
close to the abdominal cavity," Kemmerly points out. "I've seen some nasty
infections that required lancing -- opening up the area and taking out the belly
button ring."
The belly area also takes longer to heal from a piercing -- some six to nine
months, compared with two to three months in other areas, according to Mayers.
And it's an intrinsically dirty area.
Ear lobes, of course, present fewer problems than other parts of the body. But
ear cartilage is an entirely different story. Because this area doesn't have
much of a blood supply, any infection that does develop will not heal as well or
as quickly.
The Oregon case is instructive. Here, two things had gone wrong.
First, the cartilage had been pierced with spring-loaded "guns," which are
prohibited for that use in many states, including Oregon. Second, the piercing
booth, located within a mall, had inadequate sterilization procedures. One of
the workers had sprayed the sterile gun with a commercial disinfectant that had
the bacterium flowering in it.
Is there such a thing as safe body piercing?
"There is a way to do it right," Texas Tech's Armstrong says. "The biggest thing
is to have a knowledgeable artist that is in a clean environment that is
concerned about adhering to regulations."
The main rules: Don't do it yourself and don't go to the local mall.
"I would recommend the body piercing studios before I would even go to the
mall," Armstrong says. "They have fewer problems because they're in the business
of doing this as opposed to 14- and 16 year-old girls who are doing it in the
mall with no training and no concern for what they're doing."
Which doesn't mean you're home free, even if you go the studio route.
"For a lot of people who get this now, there seems to be a sense of
self-expression," Mayers says. "If you want to do it, you should do it with as
little risk as possible. But there's nobody who can tell you there's no risk at
all."
More information
For more on the risks of body piercing, visit the University of Iowa Health
Care.
Already have a piercing infection? Learn what to do from the University of
Wisconsin-Madison.

More Evidence Antidepressants Cool Hot Flashes

2008-10-24 12:15:43

More Evidence Antidepressants Cool Hot Flashes
38 minutes ago
By Alison McCook
NEW ORLEANS (Reuters Health) - Research presented here Wednesday added Paxil to
the list of antidepressants that appear to ease one of the most noxious symptoms
of menopause: hot flashes.
Traditionally, women have turned to hormone replacement therapy to relieve hot
flashes, a treatment that recently came under fire when reports suggested it can
increase the risk of cancer and heart disease.
This newest paper and other recent findings suggest that women may have another
option in the newer forms of antidepressants, which appear to reduce hot flashes
without the additional risk of hormone treatment, study author Erica Wetherhold
of GlaxoSmithKline -- maker of Paxil and funder of the current research -- told
Reuters Health.
Among a group of post-menopausal women treated for six weeks, up to 65 percent
of those given Paxil (paroxetine) experienced a drop in the number and severity
of hot flashes they experienced each day, an improvement seen in only 38 percent
of women taking placebo, or an inactive drug.
The effect of Paxil on hot flashes is similar to that seen in other types of
newer antidepressants, such as Prozac (fluoxetine) and Effexor (venlafaxine),
Wetherhold noted.
Consequently, Paxil is "just another option," she said.
Previous research has also shown that Paxil reduces depression and anxiety, two
symptoms that can also accompany menopause, Wetherhold said. Consequently, for
some women, the drug may help with multiple aspects of menopause, she added.
Paxil is "a nice option, especially for women that do find the irritability and
the anxiety to worsen around that menopausal time," she noted.
She and her colleagues presented their findings Wednesday during the 51st annual
clinical meeting of the American College of Obstetricians and Gynecologists.
During the study, 165 postmenopausal women experiencing at least two to three
hot flashes every day or 14 per week, took either daily placebo or Paxil, at
doses of either 12.5 milligrams or 25 milligrams.
None of the women were suffering from depression or anxiety, and all kept a hot
flash diary to record their symptoms.
After six weeks of treatment, the researchers found that women on 12.5
milligrams of Paxil experienced a 62-percent drop in the severity and frequency
of hot flashes, while those on the higher dose saw a 65-percent decrease in
symptoms.
In contrast, women taking placebo reported only a 38-percent decrease in the
severity and frequency of their hot flashes.
Women taking Paxil reported similar side effects to those seen in previous
studies, including headache, nausea, insomnia and sleepiness. Those taking the
higher dose tended to report more side effects than women on the lower dose.
Since the two doses appeared to have a roughly similar effect on hot flashes,
Wetherhold recommended that women who take the drug for this purpose start on
the lower dose, then perhaps work their way up.
The benefits of the two doses "were so close, that I would honestly start the
patient at the lower dose," she said.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Better Working Conditions May Improve Patient Care (DUH!)

2008-10-24 05:38:02

Better Working Conditions May Improve Patient Care
48 minutes ago
NEW YORK (Reuters Health) - Boosting nurse staffing levels in hospitals and
nursing homes and improving communication between hospitals and other healthcare
providers could lead to better patient care, the federal Agency for Healthcare
Research said on Friday.
Such measures are among a handful of effective strategies for improving patient
safety gleaned from a review of 115 existing studies on healthcare working
conditions in healthcare and non-healthcare settings, AHRQ said.
A new report developed for AHRQ by the Evidence-based Practice Center at Oregon
Health & Science University in Portland, Ore., helps shed light on what
healthcare providers can do to improve the quality of healthcare.
In addition to the recommendations on staffing and communication, the report
concludes that preventable complications are less likely when complex, technical
procedures are handled by physicians who do them frequently. It also finds that
fewer staff interruptions and distractions will likely reduce medical errors and
that, for some types of clinical care, more experience means better patient
outcomes.
A summary of the report is available on AHRQ's Web site ( www.ahcpr.gov ). The
full report will be available later this spring.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Iressa for lung cancer

2008-10-24 01:20:37

U.S. to Decide on AstraZeneca Drug as Deaths Rise
44 minutes ago
By Mark Potter
LONDON (Reuters) - Europe's second-biggest drugmaker, AstraZeneca Plc, said on
Friday its lung cancer drug Iressa had been linked to 69 new deaths in Japan,
just days before it hopes to win U.S. approval for the medicine.
Most analysts think the U.S. Food and Drug Administration (news - web sites)
(FDA) will give a green light for Iressa to go on sale in the world's biggest
drug market, noting the medicine is given only to seriously ill people for whom
other therapies have failed.
"I think probability is on its (Iressa's) side, but it's going to be for a
limited indication," said Howard Miller, an industry analyst at stockbroker
Teather & Greenwood. He forecasts peak annual sales of $550 million for Iressa.
Iressa (gefitnib) is one of a number of new medicines that AstraZeneca hopes
will make up for declining sales of ulcer pill Losec, sold as Prilosec in the
United States, which is now facing cheap, copycat competition.
Its prospects have been clouded by the series of deaths in Japan and revenues
from the drug in that country fell to $19 million in the first quarter of this
year from $41 million in the last three months of 2002.
AstraZeneca said on Friday that, according to the Japanese health ministry, the
number of people who had died after taking Iressa had risen to 246, and that
some 616 patients had suffered side effects since the drug's launch in July
2002.
However, a spokesman also said the proportion of patients developing
interstitial lung disease -- a potentially deadly condition linked to Iressa --
had "plateaued" and that the Japanese health ministry continued to back the
medicine.
"The ministry has no problems with the benefits versus risks (of the drug)," the
spokesman told Reuters.
U.S. DECISION IMMINENT
An FDA advisory panel backed Iressa in September as a last resort treatment for
advanced lung cancer, and the regulator is expected to make a final ruling by
Monday.
"I think it will just about make it," said Paul Diggle, an industry analyst at
WestLB Panmure, though he is forecasting peak annual sales of just $250-300
million.
AstraZeneca received a boost on Thursday when Australia became the second
country to back the sale of the drug.
But on the same day a U.S. consumer group, Public Citizen, said Iressa was
"likely ineffective and dangerous" and should not be approved in the world's
biggest market for medicines.
Iressa is a pill designed to shrink tumors without the side effects of
chemotherapy and belongs to a new family of drugs known as epidermal growth
factor receptor inhibitors, which caused great excitement among cancer
specialists when they were first discovered.
Sales prospects suffered a setback last year, however, when Iressa failed to
work in trials combining it with other drugs.
Iressa's initial use is for patients with advanced non-small cell lung cancer
who have previously received chemotherapy. Lung cancer is the leading cause of
cancer deaths worldwide, and about 80 percent of cases are non-small cell lung
cancer.
Longer-term, AstraZeneca also hopes the drug will have a role in the treatment
of other cancers.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Itching

2008-10-23 13:09:27

Wish there was an easy answer for all the itching that we are all doing!
:-( Mine was exacerbated during treatment but got better after I stopped
treatment. I tried everything anyone suggested from apple cidar vinegar,
oatmeal, aveeno, clorox, hydrogen peroxide and a myriad of ointments given
by Hepatologist and Dermatologist and pills like phenobarbital and atarax
but nothing helped until it finally got better on its own after treatment.
I wish you luck with it and sadly it does seem to be a common effect from
the Hep.........Take care! BTW........ you are still not posting to the
group........ just to me :-) You need to go to

Positive thoughts from a friend :-)

2008-10-23 10:10:39

Titled "Too Busy for a friend" when it got to me... May 2, 2003
One day a teacher asked her students to list the names of the other
students in the room on two sheets of paper, leaving a space between each name.
Then she told them to think of the nicest thing they could say about each of
their classmates and write it down.
It took the remainder of the class period to finish their assignment, and as the
students left the room, each one handed in the papers.
That Saturday, the teacher wrote down the name of each student on a
separate sheet of paper, and listed what everyone else had said about that
individual.
On Monday she gave each student his or her list.
Before long, the entire class was smiling.
"Really?" she heard whispered. "I never knew that I meant anything to
anyone!" and, "I didn't know others liked me so much." Were most of the
comments.
No one ever mentioned those papers in class again.
She never knew if they discussed them after class with their parents, but it
didn't matter. The exercise had accomplished its purpose.
The students were happy with themselves and one another. That group of students
moved on. Several years later, one of the students was killed in Vietnam and his
teacher attended the funeral of that special student.
She had never seen a serviceman in a military coffin before. He looked so
handsome, so mature. The church was packed with his friends.
One by one those who loved him took a last walk by the coffin.
The teacher was the last one to bless the coffin.
As she stood there, one of the soldiers who acted as pallbearer came up to her.
"Were you Mark's math teacher?" he asked. She nodded: "yes."
Then he said: "Mark talked about you a lot."
After the funeral, most of Mark's former classmates went together to a luncheon.
Mark's mother and father were there, obviously waiting to speak with his
teacher.
"We want to show you something," his father said, taking a wallet out of his
pocket. "They found this on Mark when he was killed. We thought you might
recognize it."
Opening the billfold, he carefully removed two worn pieces of notebook paper
that had obviously been taped, folded and refolded many times.
The teacher knew without looking that the papers were the ones on which she had
listed all the good things each of Mark's classmates had said about him.
"Thank you so much for doing that," Mark's mother said. "As you can see, Mark
treasured it."
All of Mark's former classmates started to gather around. Charlie smiled rather
sheepishly and said, "I still have my list. It's in the top drawer of my desk at
home."
Chuck's wife said, "Chuck asked me to put his in our wedding album."
"I have mine too," Marilyn said. "It's in my diary."
Then Vicki, another classmate, reached into her purse and showed her
frazzled list to the group. "I carry this with me at all times, " Vicki
said and without batting an eyelash, she continued: "I think we all saved our
lists."
That's when the teacher finally sat down and cried. She cried for Mark and for
all his friends who would never see him again.
The density of people in society is so thick that we forget that life will end
one day. And we don't know when that one day will be.
So please, tell the people you love and care for, that they are special and
important.
Tell them, before it is too late...
AND ONE WAY TO ACCOMPLISH THIS IS: Forward this message on.
If you do not send it, you will have, once again passed up the wonderful
opportunity to do something nice and beautiful.
If you've received this, it is because someone cares for you and it means there
is probably at least someone for whom you care.
If you're "too busy" to take those few minutes right now to forward this message
on, would this be the VERY first time you didn't do that little thing that would
make a difference in your relationships?
The more people that you send this to, the better you'll be at reaching out to
those you care about.
Remember, you reap what you sow, what you put into the lives of others comes
back into your own.
MAY YOUR DAY BE BLESSED AND AS SPECIAL AS YOU ARE
My personal note: regardless of what you do with this ( perhaps obnoxious
challenge ) you are indeed special to me and I want you to know that now as so
many times I have wanted you to know that fact of my existence. I want you to
know that I remember you and cherish your presence in my life and I will
continue to do so as long as my heart beats. There are no judgements made by me
on your spirit resulting from your response to this note.
May the wind be at your back,
may gentle sun shine on your face,
may your eyes be filled with the stars.
Peace and Love,
'´¨¨)) -:¦:-
¸.·´.·´¨¨))
((¸¸.·´ ..·´ -:¦:-Pam
-:¦:- ((¸¸.·´*
"There are many intelligent species in the universe. They are all owned by
cats." - Anonymous
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

Scientists Study Chinese AIDS Patients Who Have Resisted SARS Infection

2008-10-23 09:15:34

http://www.hivandhepatitis.com/sars/docs/050203a.html
Scientists Study Chinese AIDS Patients Who Have Resisted SARS Infection
Scientists are studying a group of several dozen Chinese AIDS patients who
appear to have resisted infection with the severe acute respiratory syndrome
(SARS) virus, even though they were treated in the same ward as SARS patients,
Long Island Newsday reports.
At the peak of the SARS outbreak in Guangzhou, the southern Chinese city in
which the epidemic is thought to have started in November 2002, patients with
the then unidentified "mystery" illness were treated on the same hospital floor
as AIDS patients. While SARS patients were treated on the opposite side of the
floor, doctors and nurses traveled back and forth between the groups, treating
both groups of patients.
Although some of the health care workers developed SARS, none of the several
dozen AIDS patients or any of their HIV-positive visitors developed the disease.
Dr. Cheng Feng of the China/UK HIV/AIDS Project speculated that the
antiretroviral drugs that are used to treat HIV/AIDS could block SARS infection.
Dr. Yuen Kowk-yung of the University of Hong Kong and Dr. David Ho of the Aaron
Diamond AIDS Research Center are exploring the possibility that antiretroviral
drugs could protect against SARS. A Chinese AIDS advocate who asked to be
identified only as Thomas said that the relationship between the two diseases
may be more complicated. Most Chinese patients only have access to the cheapest
and least effective antiretroviral regimens. These antiretrovirals target a
chemical that is not present on the coronavirus that has been identified as the
cause of SARS, Thomas said, according to Newsday.
Weakened Immune System Provides Protection Against SARS?
Scientists have speculated that the SARS virus does not actually kill human
cells but provokes an overreaction in the immune system. The immune system is
thought to destroy cells in the lungs and other parts of the body, causing acute
pneumonia.
Because death due to SARS may be the result of an overactive immune system
response, scientists speculate that HIV patients' weakened immune systems may
put them at a lower risk of developing the disease. The theory is supported by
the fact that the most effective treatment for SARS thus far is steroids --
drugs that stifle the immune response (Garrett, Long Island Newsday, 4/30).
SARS Death Rate Is Rising
The SARS death rate from SARS is rising, with mainland China accounting for more
cases than the rest of the world. Worldwide there are now more than 5,600 cases
of SARS. 3,647 of the cases are in China.
Mainland China announced 187 new SARS cases and 11 more deaths on Thursday, the
country's ministry of health said. China has now reported 170 deaths. The head
of the WHO's clinical network, Mark Salter, says current death rates are at 6
percent, but could likely reach 10 percent.
The disease is still in its early stages, Salter said, and it was normal for
death rates to increase in such circumstances.
Millions of Chinese workers celebrated May Day on Thursday cooped up at home as
China tried to contain the deadly SARS virus by cutting short the length of the
MAY DAY holiday.
The U.S. Centers for Disease Control and Prevention Wednesday added Taiwan to
its list of travel advisory countries, which includes mainland China, Hong Kong,
and Singapore.
05/02/03
Sources
L Garrett. Baffling Resistance to SARS Seeking clues in AIDS patients.
Newsday.com. April 30, 2003.
Kaiser Daily HIV/AIDS Report. April 30, 2003.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/25/2003

Diagnosing Fibrosis in Hepatitis C: Is the Pendulum Swinging from Biopsy to Blood Tests?

2008-10-23 02:11:40

http://www.hivandhepatitis.com/hep_c/news/050203b.html
Diagnosing Fibrosis in Hepatitis C: Is the Pendulum Swinging from Biopsy to
Blood Tests?
The following editorial by NH Afdhal of the Liver Center, Beth Israel Deaconess
Medical Center, Boston, MA appears in the current (May 2003) issue of
Hepatology.
- See also the Letter to the Editor of Hepatology on this subject.
"One of the major clinical problems facing the hepatology and gastroenterology
community is how best to evaluate and manage the increasing numbers of patients
identified with hepatitis C virus (HCV). In the last decade, advances in
serologic and virologic testing for HCV and improvements in therapy have led
more patients to be identified and to seek treatment.
However, little progress has been made in improving either our ability to
determine the degree of hepatic injury, particularly fibrosis, or to predict the
risk of disease progression for the individual patient. This information still
requires an old fashioned liver biopsy.
The clinician relies on the biopsy results for both prognostic and therapeutic
decision making, which can have a major impact on the patient's life. While we
certainly are daunted at the prospect of performing 3 million liver biopsies
with the associated cost, manpower issues, and risk for patient injury, we need
to have a reliable alternative that can just as effectively guide our decision
analysis.
"Multiple histologic scoring systems have been proposed for the grading of HCV
inflammation and the staging of HCV fibrosis, including the commonly used
METAVIR and Ishak scoring systems. The pathologist is able to use these systems
to grade the inflammatory component of HCV and stage the degree of fibrosis.
Repeat liver biopsies can determine the effect of therapy on improving liver
inflammation and fibrosis and the true rate of disease progression in
individuals who decline therapy. Perhaps the first question we should ask is,
how good is our gold standard of liver biopsy for staging HCV-induced liver
fibrosis? A single-pass liver biopsy is able to correctly diagnose the stage of
fibrosis or presence of cirrhosis in 80% of patients.
Factors that improve the diagnostic accuracy of liver biopsy include the
presence of a uniform disease throughout the liver such as HCV, multiple passes,
use of a Trucut 15-gauge needle rather than Menghini type needles, and an
unfragmented biopsy core of 2 cm or greater in length. Even with experienced
physicians performing the liver biopsy and expert pathologists interpreting the
biopsy, our gold standard has up to a 20% error rate in staging disease.
"In addition, the actual role of liver biopsy in HCV is controversial. The liver
biopsy is not necessary to make the diagnosis and rarely is it of value in
excluding secondary diagnoses such as coexistent, autoimmune, iron, nonalcoholic
steatohepatitis or alcohol-induced injury.
The major clinical utility of the index biopsy in HCV is to enable the clinician
to determine the need for therapy. Because of the complexity and side effects of
interferon-based therapies for HCV, the liver biopsy has taken an increasing
role in the clinician's decision whether to treat a patient.
Patients with significant liver fibrosis (METAVIR
inflammation are all considered as suitable for therapy, whereas patients with
milder disease are often not as aggressively offered treatment. However, as
therapy for HCV improves, the clinical need for a biopsy may be less apparent.
For example, genotype 2 and 3 patients have a greater than 70% sustained
virologic response with pegylated interferons and ribavirin, and in
uncomplicated cases a rationale can be made to treat all these patients without
liver biopsy and only to biopsy those who fail treatment.
As newer, better tolerated, and more efficacious therapies are developed, the
need for biopsying all HCV patients to grade and stage disease may become
redundant. Therefore, the development of noninvasive tests that can
differentiate between patients with mild disease (METAVIR F0 or F1) versus those
with more significant fibrosis (METAVIR F2-F4) could have a widespread clinical
utility in managing HCV patients in the future.
This concept of attempting to use noninvasive serum tests to classify patients
as having mild or significant liver fibrosis was addressed in a recent
publication by Forns et al. and in several letters in this issue of Hepatology.
Forns examined a selected cohort of patients with HCV and, by using multiple
logistic regression, identified age and 3 commonly performed serum tests that
could be used to predict patients with F0/F1 disease. They derived a formula
giving a numerical score in an initial population of 351 HCV patients, which was
based on the patient age combined with single estimations of glutamyl
transpeptidase (GGT), cholesterol level, and platelet count.
This score was then validated in a prospective group of 125 patients, in which
92 patients had mild fibrosis and 33 patients had significant fibrosis. A score
of less than 4.2 was seen in 47 patients of whom 45 (96%) had stage F0/F1 giving
an overall accuracy of 96% in identifying patients with mild fibrosis. A score
of greater than 6.9 was taken as the high cutoff point for significant fibrosis.
Only 10 of 33 patients with stage F2 to F4 were identified by this scoring
system, and 15 patients with F0 to F1 were incorrectly classified as having
advanced disease. The authors concluded that this relatively simple, inexpensive
fibrosis scoring system could prevent the need for a liver biopsy in one third
of patients with mild disease.
Certainly, on preliminary analysis this looks promising but there are several
important considerations. First, the patient population was highly selected to
exclude patients over 65 years of age, those with regular alcohol consumption,
obese patients, and patients coinfected with HBV or human immunodeficiency
virus.
More importantly, only 51% of the patients studied could actually be classified,
and the scoring system was indeterminate for the remainder of the patients who
scored between 4.2 and 6.9. Therefore, the widespread applicability of such a
fibrosis scoring system might be limited.
Interestingly, two separate groups have validated the findings of Forns et al.
in separate cohorts of HCV patients. Patel et al. in their letter in this
edition of HEPATOLOGY applied the Forns scoring system to 110 HCV patients.
A score of less than 4.2 had a negative predictive value of 89%, but 59% of
patients were again in the indeterminate group and could not be classified.
Thabut et al. in their letter compare the Forns score to the previously
published FIBROTEST.
The FIBROTEST utilizes 5 less commonly used biomarkers for fibrosis including
apolipoprotein A1, haptoglobin, alfa 2 macroglobulin, GGT, and total bilirubin.
In their retrospective analysis, the FIBROTEST appeared slightly better at
diagnosing significant fibrosis and showed a more linear correlation with degree
of fibrosis than the Forns scale.
Both FIBROTEST and the Forns scale were excellent at excluding fibrosis, but the
FIBROTEST had a greater positive predictive value (90%) for diagnosing advanced
fibrosis. However, it is critical to point out that neither of these tests can
truly distinguish between the different histologic stages of fibrosis. In
addition, the FIBROTEST has similar issues with a large percentage of patients
falling into an indeterminate group.
The inability to classify large numbers of patients is not surprising because
neither of these systems really measures fibrosis but they both rather reflect
alterations in hepatic function associated with progressive disease. More
recently, combining markers of extracellular matrix (ECM) such as tissue
inhibitor of metalloproteinase and hyaluronic acid with alfa 2 macroglobulin, a
marker of hepatic function, has been evaluated by Patel et al. This combination
of fibrosis markers has a similar ability to differentiate F0/F1 from F2 to F4
and reduces the number of patients (20%-30% depending on fibrosis prevalence)
falling into the indeterminate range.
First, all of these investigators should be congratulated for pursuing
clinically relevant noninvasive methods to measure liver fibrosis. There is
little doubt that we need such surrogate fibrosis markers or scoring systems for
HCV, particularly as we start to develop a new generation of antifibrotic
therapies.
Several large studies are already in progress to evaluate both alfa and gamma
interferons as antifibrotic agents in HCV and all are relying on serial liver
biopsies as the primary outcome determinant. However, biopsies remain a static
determinant of the mass of fibrosis at a given time, and an antifibrotic agent
could be highly effective in ECM remodeling but show little change on biopsy.
This is where the utility of true fibrosis markers is critical. An ideal
noninvasive surrogate marker of liver fibrosis should be liver specific; not
influenced by alterations in liver, renal, or reticuloendothelial cell function;
reproducible; and easy to perform.
These markers should also reflect the stage of fibrosis for diagnostic purposes
and the dynamic balance of matrix deposition and removal. Finally, they should
be specific for liver fibrosis from any cause and be independent of any
associated hepatic inflammation.
Advances in our understanding of the hepatic ECM has led to many potential
markers being identified, but none have sufficient merit for clinical use as
solitary markers. A large multicenter European study combining multiple markers
that measure ECM production and breakdown has shown promise in the diagnostic
staging of liver disease, and further longitudinal studies from this cohort are
awaited.
So, are surrogate markers of liver fibrosis ready for clinical primetime? We
could argue from the study by Forns et al. and the FIBROTEST that we can, to
some extent, categorize almost a third of patients into those with mild disease
and use this information for decision analysis without a liver biopsy.
Unfortunately, there is somewhat of a rush to commercialize these so-called
tests of liver fibrosis without rigorous scientific validation. I would propose
that the clinical acceptance of fibrosis markers will depend on their fulfilling
the ideal characteristics listed above.
We need to focus basic and clinical research efforts on identifying better
fibrosis markers and exploring how to incorporate them into clinical practice.
The study of Forns et al. and others are a good beginning in our quest for
surrogate markers, but for the moment, the pendulum still favors biopsy over
blood."
05/02/03
Reference
NH Afdhal. Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from
biopsy to blood tests? Hepatology 37 (5): 972-974. May 2003.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/25/2003

Extending Peginterferon Plus Ribavirin Therapy to 72 Weeks in Late Responders with Genotype 1

2008-10-22 16:29:18

http://www.hivandhepatitis.com/hep_c/news/050203a.html
Extending Peginterferon Plus Ribavirin Therapy to 72 Weeks in Late Responders
with Genotype 1 Chronic HCV Can Produce a Sustained Virologic Response
Most HCV-infected individuals in the US have genotype 1 HCV, which is the most
difficult genotype to treat successfully. In patients with HCV genotype 1, the
sustained virologic response (SVR) to 48 weeks of treatment with peginterferon
plus ribavirin (the current standard of care) is about 42%.
Study results suggest that one primary factor in SVR is rapid hepatitis C virus
(HCV) RNA clearance, which ranges from 75% for patients who clear in 12 weeks to
only 32% for those who lose HCV RNA at week 24.
Some researchers propose that extending therapy in patients who cleared HCV RNA
between weeks 12 and 24 (i.e., late responders) could increase SVR.
In a Letter to the Editor of the current issue of Hepatology (May 2003),
researchers at the Liver Clinic, Gastroenterology Institute, in Kaplan, Israel
describe results of a small study in nine patients:
"We selected 9 patients with chronic hepatitis C who were infected with genotype
1 in treatment with pegylated interferon alfa-2b plus ribavirin who cleared HCV
RNA between weeks 12 and 24 for therapy prolonged to 72 weeks. Three were men
and 6 were women, with a median age of 41 ± 14.57 years. All patients had
elevated alanine aminotransferase levels, positive HCV RNA, and a liver
examination showing chronic hepatitis.
"Patients were treated with a mean dose of 1.0 microgram/kg of peginterferon
alfa-2b once weekly (PEG-Intron) plus 800 mg/d of ribavirin (Rebetol). HCV RNA
was analyzed by using a quantitative, real-time, reverse-transcriptase
polymerase chain reaction technique with a lower limit of detection of 100 IU/L.
"Eight patients completed therapy and 6 months of follow-up. One patient stopped
therapy at week 48 because of thyroid alterations. Table 1 shows patient
characteristics and changes in HCV-RNA levels from baseline to week 12. .
Table 1. Baseline Characteristics of the 9 Patients Treated and HCV-RNA
Changes in Logs From Baseline to Week 12 and HCV-RNA Decline From Baseline to
Week 12
Case
Sex
Age (y)
Histology
ALT (UI/L)
HCV-RNA (UI/mL) Logs Baseline
HCV-RNA (UI/mL) Logs Week 12
HCV-RNA Decline Logs Between Baseline and Week 12
1
M
41
Moderate CAH
75
5.97
2.04
-3.93
2
M
36
Moderate CAH
186
5.40
3.00
-2.40
3
F
35
Mild CAH
95
6.23
2.68
-3.55
4
F
63
Moderate CAH
90
5.84
2.04
-3.80
5
F
61
Moderate CAH
83
6.61
3.38
-3.23
6
M
30
Moderate CAH
97
6.18
2.92
-3.31
7
F
52
Moderate CAH
104
6.23
2.81
-3.36
8
F
20
Moderate CAH
89
5.48
2.30
-3.18
9
F
52
Moderate CAH
78
5.47
2.18
-3.29
Abbreviations: ALT, alanine aminotransferase; CAH, chronic active
hepatitis.
"In all patients, HCV RNA was positive at week 12 of therapy but undetectable at
week 24 and throughout the 72 weeks of therapy. At week 24 of follow-up, 7
patients maintained an SVR and one relapsed (case 3).
"This study, with a small number of patients, showed that prolonged combination
therapy with peginterferon and ribavirin is very useful in late virologic
responders because it increases SVR. HCV-RNA determination has an important role
not only in the decision to stop therapy but also in better adjusting therapy.
"Currently, nonresponders can be detected by a quantitative HCV-RNA test at week
12, showing a decline of less than 2 logs in HCV-RNA concentrations. In these
patients, combination therapy should be stopped because the probabilities of a
sustained response are almost nil. In patients who achieve an early virologic
response, the probabilities of achieving an SVR were 80% for those who cleared
HCV RNA at week 12 and sooner, and 40% for those who achieved a 2-log reduction
in HCV-RNA concentrations but still remained HCV-RNA positive as a recent review
of multicenter studies has shown.
"All of our patients had a 2-log decline but remained HCV-RNA positive at week
12 and, taking into account the previous results, their probabilities of
achieving an SVR are lower than those patients who were HCV-RNA negative at week
12. In this subgroup of patients, with a slower decline in HCV-RNA levels,
usually genotype 1 patients with high baseline viral levels, continuing therapy
to 72 weeks could be the best way to ensure an SVR with acceptable tolerability
and safety.
"In summary, extending therapy with peginterferon alfa plus ribavirin to 72
weeks for late virologic responders may induce a higher SVR. These results merit
further prospective, randomized, controlled studies, using the optimal doses of
peginterferon and ribavirin for longer duration versus the current standard
48-week therapy in this subset of patients."
05/02/03
Reference
M Buti and others (Liver Clinic, Gastroenterology Institute, Kaplan, Israel).
Extending combination therapy with peginterferon alfa-2b plus ribavirin for
genotype 1 chronic hepatitis C late responders: A report of 9 cases. Letter to
the Editor. Hepatology 37 (5):1226. May 2003.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/25/2003

Vitamins: More May Be Too Many

2008-10-22 11:50:04

Vitamins: More May Be Too Many
April 29, 2003
By GINA KOLATA
A growing number of medical experts are concerned that
Americans are overdoing their vitamin consumption. As many
as 70 percent of the population is taking supplements,
mostly vitamins, convinced that the pills will make them
healthier.
But researchers say that vitamin supplements cannot correct
for a poor diet, that multivitamins have not been shown to
prevent any disease and that it is easy to reach high
enough doses of certain vitamins and minerals to actually
increase the risk of disease.
No longer, the experts say, are they concerned about
vitamin deficits. Those are almost unheard of today, even
with the population eating less than ideal diets and
skimping on fruits and vegetables. Instead, the concern is
with the dangers of vitamin excess.
"There has been a transition from focusing on minimum needs
to the reality that today our problem is excess - excess
calories and, yes, excesses of vitamins and minerals as
well," said Dr. Benjamin Caballero, a member of the Food
and Nutrition Board at the National Academy of Sciences and
the director of the Center for Human Nutrition at Johns
Hopkins University.
Dr. Caballero said that for some supplements, including
vitamin A, the difference between the recommended dose and
a dose that could lead to bad outcomes like osteoporosis
was not large. Popular multivitamins, he added, often
contain what could be risky doses.
"Certainly," he said, "by consuming supplements, people can
reach that level."
Doctors who once told patients that multivitamins were, at
worst, a waste of money now say they are questioning that
idea.
"All of a sudden, scientists are rearing back and saying,
`Wait a minute, do we really know that we need this and do
we really know that we need that?' " said Dr. Ruth Kava,
nutrition director at the American Council on Science and
Health, a consumer foundation in Manhattan that is in part
financed by industry.
With vitamin A in particular, it is easy to step over the
edge into a danger zone, said Dr. Joan McGowan, chief of
the musculoskeletal diseases branch at the National
Institute of Arthritis and Musculoskeletal and Skin
Diseases.
"You can be eating Total cereal, drinking fortified milk,
taking a multivitamin," Dr. McGowan said. "You can get into
a situation where you're getting more than you need. Until
recently, there was little concern about vitamin A and bone
health."
Now, she added, "we may have to rethink the issues."
Similar questions are being raised about other vitamins and
minerals, notably iron and vitamins E and C.
Researchers say the questions involve multivitamins taken
by healthy people, not specific vitamins or minerals taken
by groups with specific needs. Some elderly people, for
example, may be deficient in vitamin B12 because they lose
their ability to absorb it from foods. People who spend
little time outdoors may require vitamin D, which the skin
makes when it is exposed to sunlight. Even when older
people are in the sun, aging skin loses much of its ability
to synthesize the vitamin.
Pregnant women who do not receive enough folic acid, a
vitamin in fruits and vegetables that is added to enriched
flour, are at increased risk of having babies with neural
tube defects. Because the vitamin is needed at the very
start of pregnancy, some advocate folic acid supplements
for all who might become pregnant, just to be sure they are
protected.
For most people, however, the issue is not deficits.
Instead, nutrition researchers ask: Do people eating
relatively healthy diets with fresh fruits and vegetables
and not too many calories or fats benefit from
multivitamins or other supplements? Do those whose diets
are abysmal, heavy on fast foods and lacking in fruits and
vegetables, make up for some deficits if they take
multivitamin pills?
Dr. Annette Dickinson, president of the Council for
Responsible Nutrition, a group that represents the
supplement industry, says 70 percent of Americans sometimes
take supplements - usually multivitamins or individual
vitamins and minerals - and 40 percent take them regularly.
"Our position," she said, "is that most people, literally
most people, would benefit from taking a multivitamin every
day. It's insuring adequate and even generous intake of all
the nutrients."
The most popular individual supplements are vitamins C and
E, said Dr. Robert M. Russell, the director the Human
Nutrition Research Center of Agriculture Department at
Tufts University, who is head of the Food and Nutrition
Board. Scientists once thought those vitamins could help
prevent ailments like cancer and heart disease, but
rigorous studies found no such effects.
Vitamin E supplements can increase the risk of heart
attacks and strokes, and studies of vitamin C supplements
consistently failed to show that it had any beneficial
effects.
"The two vitamins that are the most not needed are the ones
most often taken," Dr. Russell said.
Excess vitamin C is excreted in the urine, but excesses of
some other vitamins are stored in fat, where they can build
up. Of particular concern, researchers say, is vitamin A.
It is found in liver, and small amounts are added to milk.
But for most people who are reaching worrisome levels, the
main source is supplements, multivitamins, nutrition bars,
health drinks and cereals.
Several recent large studies indicate that people with high
levels of vitamin A in their blood have a greater risk for
osteoporosis. People can easily reach a potentially
dangerous level, about five times the recommended dose, by
taking vitamins and supplements, nutrition researchers say.
Some popular multivitamins run 1,500 micrograms a pill,
twice the recommended daily amount and a level that, in one
recent study, doubled the risk of bone fractures. Some
supplements provide as much as 4,500 micrograms a day, well
above the level that the National Academy of Sciences calls
an upper limit for safety.
"If you have a good source of vitamin A in your food and
you take a supplement with another 100 percent, you can
easily reach a level that can accumulate" to one associated
with increased risk of osteoporosis, Dr. Caballero said.
Dr. Dickinson said that multivitamin manufacturers were
decreasing the vitamin A in their products, but that it
might take a year for the reformulated products to appear.
Others warn about overdosing on other vitamins and
minerals.
Dr. Richard J. Wood, director of the mineral
bioavailability laboratory at Tufts, worries about iron
overload, which can increase the risk of heart disease. In
a large federal research effort, the Framingham study, Dr.
Wood found that 12 percent of the elderly participants had
worrisome levels. "Hardly anyone had iron deficiency
anemia," he said. "But 16 percent were taking
iron-containing supplements."
While readily noting that the proof of a benefit is not in,
some researchers said they took multivitamins. They agree
with Dr. Joann E. Manson, chief of preventive medicine at
Brigham and Women's Hospital in Boston, who takes a
multivitamin and recommends it to patients whose diets seem
imbalanced.
"I think it's a good form of insurance," Dr. Manson said.
"I don't think there's a significant downside. We don't
have the evidence yet that it is beneficial."
Dr. Robert H. Fletcher, a professor of ambulatory medicine
at Harvard Medical School, also takes multivitamins. For
him, the deciding factor was whether he ingested enough
folic acid. Studies have suggested that high levels of
folic acid can protect against heart disease by lowering
levels of another substance, homocysteine. High levels of
homocysteine are associated with increased risks of heart
disease, but there is no study showing definitively that
reducing homocysteine levels protects against heart
disease.
So far, the folic acid studies are suggestive, not
definitive. But Dr. Fletcher said, "If I were a betting
man, I'd bet on it."
But a European study, reported recently at a meeting of the
American College of Cardiology, found that folic acid
supplements actually made matters worse for heart disease
patients. The study, the Folate After Coronary Intervention
Trial, involved 626 patients who were having stents
inserted into blocked arteries to keep them open. Half were
randomly assigned to take folic acid, and the rest took a
placebo. Six months later, the arteries of those taking
folic acid were significantly narrower than the arteries of
those taking a placebo, exactly the opposite of what the
investigators had expected.
A previous study, however, had found that folate helped
such patients. Dr. Eric Topol, an interventional
cardiologist at the Cleveland Clinic, said he thought the
truth was that it was neither helpful nor harmful for most
people. "Over all, the likely explanation is that there is
a neutral effect, and these relatively small trials found
opposite findings due to the play of chance," he said.
Dr. Topol said B vitamins, like folic acid, "can't be
recommended" at this point, except for people with
extremely high levels of homocysteine, and even then their
value has not been rigorously demonstrated.
Karen Miller-Kovach, chief scientist for Weight Watchers
International, has a compromise. She takes a child's
multivitamin, with its much lower levels of vitamins and
minerals.
"It is virtually impossible to find an adult multivitamin
and mineral supplement that is only 100 percent of the
R.D.A.," Ms. Miller-Kovach said. "All are 150 percent or
so. I worry about getting too much and I worry about
imbalances. They put in more of the things that are
inexpensive, like B vitamins and things with consumer
appeal like vitamin C. The formulas are based on market
forces, not nutritional needs."
Others decided against taking the pills.
Dr. Kava, of the
American Council on Science and Health, said she abstained.
"People ask me what vitamins I take," she said. "I say I
don't take any. They look at me askance. They can't believe
I'm a nutritionist."
Dr. Caballero also does not take vitamins. "There is no
disease I know of that is prevented by multivitamins," he
said.
In fact, Dr. Caballero said, typical pills, which contain a
variety of minerals as well as vitamins, have ingredients
that actually cancel out one another. "Minerals antagonize
each other for absorption," he said. "Zinc competes with
iron which competes with calcium."
Dr. Caballero also notes that large, rigorous studies that
were supposed to show that individual vitamins prevented
disease ended up showing the opposite. Those who took the
vitamins actually had more of the disease it was meant to
prevent.
Two large randomized trials of vitamin A and beta carotene
that researchers hoped would show a protective value
against cancer found no benefit, and one found that
participants who took the supplements had more cancer.
A large study of vitamin E and heart disease found that it
did not prevent heart attacks and that people taking it had
more strokes.
Another study, of women with heart disease, found that
antioxidant vitamins might actually increase the rate of
atherosclerosis.
Dr. Caballero said people were deluding themselves if they
thought multivitamins could make up for poor diets.
"If you eat junk food every day, vitamins are the least of
your problems," he said. "You cannot replace a healthy
diet. We don't know what ingredient in a healthy diet is
responsible for which condition. We do know that people who
consume five servings or more of fruits and vegetables have
less disease. But we don't know which ingredient. We tried
beta carotene, vitamin E and antioxidants, and they didn't
work.
"People are looking for the magic bullet. It does not
exist."
http://www.nytimes.com/2003/04/29/health/nutrition/29VITA.html?ex=1052829234&ei=\
1&en=4875a3f881e027f5
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

HCV Advocate Site

2008-10-22 08:22:38

The following new items have been recently posted to www.hcvadvocate.org
HCV Advocate Medical Writers' Circle - Cirrhosis in Chronic Hepatitis C
Infection by Dr. Jorge L. Herrera. In this excellent article, Dr. Herrera
discusses the entire spectrum of HCV induced cirrhosis including diagnosis,
management and treatment.
May 2003 HCV Advocate Newsletter - This month's newsletter includes:
*A Simple Guide to Understanding the Cost of HCV Medications
*Drugs and the Liver
*Understanding Your Liver Biopsy
*The Future Burden of HCV
*HealthWise- Navigating Illness - Suggestions for Patients, Family, and
Coworkers
*Hepatitis C Viral Load: International Units versus Copies/ml - What Are the
Differences?
*Bayer Receives Viral Load Approval
*FDA: Drug Information - A link to the FDA web site that will provide
information on many prescription and over-the counter drugs.
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/25/2003

SARS Roundup

2008-10-22 00:39:59

SARS Roundup
- Disease contained in some places, but not China
- Quarantines, travel bans proving effective
- Chinese economy hard hit
- Toronto gets a foothold
- Experts warn against U.S. complacency
MONDAY, April 28 (HealthScoutNews) -- While the severe acute respiratory
syndrome (SARS) outbreak seems to be easing in a number of countries, it's still
spreading in China and the government there is being forced to impose more tough
restrictions aimed at confining the disease.
The World Health Organization (WHO) says Vietnam, which has no new reported SARS
victims, is the first country to contain SARS. And the situation seems to be
improving in Canada, Hong Kong and Singapore as they report fewer cases of the
highly infectious respiratory disease each day, the Associated Press reports.
On Monday, China reported eight new SARS deaths. There were five SARS deaths in
Hong Kong and one in Singapore. The total number of SARS deaths worldwide stands
at 333, with more than 5,000 people infected with the disease.
Most of the SARS deaths and cases have been in China and Hong Kong. As of
Monday, there have been 140 SARS deaths in China and 3,106 of its people have
been infected. The number of new confirmed cases rose by 203 from Sunday to
Monday, the AP says.
In Hong Kong, there were 14 new cases reported Monday. That's the lowest
increase in new cases since Hong Kong started releasing daily statistics last
month.
The AP reports that Asian countries are using travel restrictions and
quarantines to combat the spread of the disease. Taiwan imposed a 10-day
quarantine for visitors traveling from areas that are SARS hotspots.
Chinese officials are using strict measures in their attempts to curb the spread
of SARS. In Beijing, police are stopping cars to check people for symptoms of
the disease. The city's cinemas, theatres, and other public entertainment
outlets have been closed.
On Sunday, China closed its border with Nepal in an effort to prevent the
disease from spreading to that small country.
The New York Times reports that the SARS outbreak is hammering the Chinese
economy. Retail sales have plummeted, there's a weakened demand for some Chinese
exports, and domestic and foreign tourism have evaporated.
The Chinese economy shriveled by an annual rate of 2 percent in the second
quarter. In the first quarter of the year, before the SARS crisis, it was
growing by an annual rate of 9.9 percent, J.P. Morgan Chase told The Times.
In Hong Kong, a team of WHO experts plans to investigate factors that may
contribute to the possible environmental transmission of SARS. The team will
study Hong Kong's sewage, ventilation and plumbing systems, along with its
architecture and population distribution, Channel News Asia reports.
In Toronto, officials announced that a 21st person died of SARS on the weekend
and as many as five other people remain in critical condition and may not
survive, CBC News reports.
But public health experts there say the disease is under control and predict
that the number of SARS cases will continue to drop. The last reported new case
of SARS in the Toronto area was on April 9 and the total number of new or
suspected cases has dropped to 267.
Toronto received some potential good news over the weekend, when the WHO said it
would review a travel advisory recommending that people avoid non-essential
travel to Toronto.
The WHO issued the travel advisory last Wednesday and originally said it would
remain in place for 3 weeks. The move was loudly condemned in Toronto as being
unnecessary and a serious threat to the city's economy.
While SARS hasn't had as large an impact in the United States as in some other
countries, it's still causing ripples. A foreign tourist arriving in New York
City earlier this month was involuntarily detained in a hospital for 10 days
after arriving with suspected SARS symptoms, The New York Times reports.
It's only the second time in the last 25 years that the city's Health Department
has exercised its power to involuntarily isolate a person for a disease other
than tuberculosis.
While the U.S. seems to have dodged the SARS bullet, medical experts say the
country shouldn't develop a false sense of security, The Washington Post
reports.
Several top doctors say the U.S. has been lucky so far and it would be dangerous
to assume that SARS won't strike the country in large numbers.
More Information
For more about SARS, visit the World Health Organization or the U.S. Centers for
Disease Control and Prevention.
-- Robert Preidt
Copyright © 2003 ScoutNews, LLC. All rights reserved.
http://www.PersonalMD.com/news.jsp?nid=512926
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.476 / Virus Database: 273 - Release Date: 04/24/2003

How Patients Manage Life and Health While Waiting for a Liver Transplant

2008-10-21 17:47:57

How Patients Manage Life and Health While Waiting for a Liver Transplant
from Progress in Transplantation
Posted 04/18/2003
M. Susan Baker, RN, MScN, ACNP, Carol L. McWilliam, RN, MScN, EdD
Abstract and Introduction
Abstract
Liver transplantation offers a lifesaving treatment for individuals with
terminal disease. An extended waiting period may contribute to anxiety and
undermine overall health status, jeopardizing the patient's opportunity for
successful transplantation. The purpose of this grounded theory qualitative